



सत्यमेव जयते

GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL
ORGANISATION (Headquarter)
(Directorate General of Health
Services) Ministry of Health & Family
Welfare
FDA Bhavan
ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-
23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

File No. CT/25/000089

To,

M/s Parexel International Clinical Research Private Limited,
CoWrks, RMZ Eco world, Ground Floor, Bay Area –Adjacent to Building 6A,
Outer Ring Road, Devarabeesanahalli Village, BENGALURU, INDIA -560103

Sir,

With reference to your application No. GCT/CT04/FF/2025/50110 dated 26-Jun-2025, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, **“A Phase 2b Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess Efficacy and Safety of Verekitug (UPB-101) in Participants with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)” Protocol No. UPB-CP-06, version no. 1.0 dated 29 Jan 2025 with a total of up-to 40 subjects from India** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

- 1) **Human biological samples i.e. Whole blood, plasma, serum and urine related to clinical trial shall be permitted to be exported for analysis subject to the clearance by port offices of CDSCO. Further, ICMR/DHR permission shall be obtained for export of optional biological samples as per DGFT notification number 72/2023 dated 11.03.2024.**
- 2) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;
- 3) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- 4) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- 5) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- 6) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian

- Council of Medical Research before enrolling the first subject for the trial;
- 7) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
 - 8) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
 - 9) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;
 - 10) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
 - 11) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
 - 12) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
 - 13) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
 - 14) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
 - 15) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
 - 16) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
 - 17) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
 - 18) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
 - 19) Merely granting permission to conduct the **clinical trial** with the Investigational Drug Product does not convey or imply that, based on the **clinical trial study data** generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;
 - 20) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licensing Authority
Stamp

FORM CT-06

(See rules 22,25,26,29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG**

1. The Central Licensing Authority hereby permits **M/s. Parexel International Clinical Research Private Limited, CoWrks, RMZ Eco world, Ground Floor, Bay Area –Adjacent to Building 6A, Outer Ring Road, Devarabeesanahalli Village, BENGALURU, INDIA -560103 Telephone No.: 8067723000 FAX: 80 67723001 E-Mail : PAREXELINDIA@PAREXEL.COM** to conduct clinical trial of the new drug or investigational new drug as per **Protocol No. UPB-CP-06, version no. 1.0 dated 29 Jan 2025** in the below mentioned clinical trial sites [As per Annexure].-
2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].
3. This permission is subject to the conditions prescribed in Part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date _____

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licensing Authority
Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	Verekitug (UPB-101)
Therapeutic class:	Immunoglobulin GI human monoclonal agent
Dosage form:	Solution for injection
Composition:	Verekitug (UPB-101) =200.0000 mg/ml In House Specification Active
Indications:	Chronic Obstructive Pulmonary Disease

Annexure:

Details of clinical trial site:

S.No.	Names and address of clinical trial site	Ethics committee details	Name of investigator
1.	Department of Pulmonary and Critical Care Medicine Pt. B.D Sharma Post Graduate Institute of Medical Sciences Near Delhi Bye Pass, Rohtak-124001, Haryana, India	Institutional Ethics Committee, Pt. BD Sharma, Post Graduate Institute Of Medical Sciences, PGIMS UHS, Rohtak-124001, Haryana India ECR/293/Inst/HR/2013/RR-24	Dr Pawan Kumar
2.	Deaprtament of Pulmonology, Aster Prime Hospitals, Opp. Passport Seva Kendra, Ameerpet, Hyderabad-500038, Telangana, India.	Ethics committee-Aster Prime Hospitals Behind mythrivanam, Beside Bluefox Hotel, Ameerpet, Hyderabad-500038, Telangana, India ECR/381/Inst/AP/2013/RR-21	Dr Boyilla Nagaraju
3.	Deaprtment of Chest Medicine, Sir Ganga Ram Hospital, SGRH Marg, Rajinder Nagar, New Delhi-110060, India	Ethics Committee Sir Ganga Ram Hospital, SGRH marg Rajinder Nagar, New Delhi-110060, India ECR/20/Inst/DL/2013/RR-2024	Dr Amit Dhamija
4.	Department of Pulmonology, Nil Ratan Sircar Medical College & Hospital, 138, AJC Bose Road, Kolkata-700014 West Bengal, India	Ethics Committee, N.R.S Medical College NRS Medical College And Hospital 138, A.J.C Bose Road Kolkata-700014 West Bengal, India	Dr Jaydip Deb

		ECR/609/Inst/WB/2014/RR-20	
5.	Department of Respiratory, Jawahar Lal Nehru Medical College, Kal Bagh, Ajmer-305001, Rajasthan, India	Institutional Ethics Committee Jawahar Lal Nehru Medical College Kala Bagh, Ajmer, Rajasthan –305001, India ECR/1156/Inst/RJ/2018/RR-22	Dr Piyush Arora
6.	Department of Pulmonary Medicine, ACSR Govt. Medical College and Hospital, Dargamitta, G.T. Road, Nellore -524 004, Andhra Pradesh, India	INSTITUTIONAL ETHICS COMMITTEE, NELLORE AC Subba Reddy Govt. Medical College and Hospital Opp. A.C. Stadium, Dargamitta, G.T. Road, Nellore - 524004, Andhra Pradesh, India. ECR/961/Inst/AP/2017/RR-20	Dr Varikuti Aparna
7.	Shree Hospital & Critical Care Centre 799, Om Nagar Opp. Tajshree Building, Sakkardara Sq.Nagpur-440009, Maharashtra, India	Shree Hospital Ethics Committee Shree Hospital Unit, Plot No. 786 A, 3rd Floor Behind Shree Hospital & Critical Care Centre, Mirchi Bazaar, Umrer Road, Sakkardara, Sq, Nagpur-440009, Maharashtra, India EC/RENEW/INST/2020/7843	Dr Akash Balki Lataru
8.	Department of Respiratory Medicine, S.P. Medical College & A.G. of Hospitals, Clinical Research Unit, Near Medicine ICU & Maharaja MRI, Bikaner -334001, Rajasthan, India	Ethics committee S.P. Medical College, S.P. Medical College, Bikaner Pawanpuri, Bikaner Rajasthan -334003 India ECR/27/SP/Inst/RR-19	Dr Rajendra Saugat
9.	Department of Pulmonology, Critical Care and Sleep, Fortis Hospital, Sector-62, Phase-8, Mohali, Punjab -160062, India	Institutional Ethics Committee, Fortis Hospital, Sector-62, Phase-8, Mohali, Punjab -160062 India ECR/28/Inst/PB/2013/RR-24	Dr Amit Kumar Mandal
10.	Shri Guru Ram Rai Institute of Medical and Health Sciences and Shri Mahant IndiresH Hospital, Patel Nagar, Dehradun -248001, Uttarakhand, India	Institutional Ethics Committee, Admin Block, Shri Guru Ram Rai Institute of Medical and Health Sciences and Shri Mahant IndiresH Hospital, Patel Nagar, Dehradun - 248001, India ECR/710/Inst/UK/2015/RR-21	Dr Jagdish Kumar Rawat

11.	Department of Respiratory Medicine, King Georges Medical University, Shahmina Road, Chowk, Lucknow ,Uttar Pradesh -226003 India	Institutional Ethics Committee, King Georges Medical University, Shahmina Road, Chowk, Lucknow, Uttar Pradesh -226003 India ECR/262/Inst/UP/2013/RR-19	Dr Ankit Kumar
12.	Department of Pulmonary Medicine, Govt. Siddhartha Medical College, Ring Road, Gunadala, Vijayawada – 520 008, Andhra Pradesh, India	Institutional Ethics Committee, SMC & GGH Govt. Siddhartha Medical College, Ring Road, Gunadala, Vijayawada –520 008,Andhra Pradesh, India ECR/633/INST/AP/2014/RR-24	Dr Vasireddy Aruna
13.	Deaprtment of Internal Medicine and Respiratory and Sleep Medicine, Medanta The Medicity, Sector-38, Gurugram -122001, Haryana, India	Medanta Institutional Ethics Committee (MIEC) & 10th Floor, A-wing (POCU), Medanta the Medicity, Sector-38, Gurugram - 122001, Haryana, India ECR/282/Inst/HR/2013/RR-20	Dr Randeep Guleria
14.	Department of Pulmonology, Rajarshee Chhatrapati Shahu Maharaj Government Medical College & Chhatrapati Pramila Raje Hospital, Dasara Chowk, Bhausinghaji road, Town Hall, Kolhapur-416012, Maharashtra, India	RCSMGMCIEC2, RCSMGMC and CPR Hospital, Building No. 2, Qurter no. 3, Room no. 7, Dasara Chowk, Bhausinghaji Road, Town Hall, Kolhapur-416012, Maharashtra, India ECR/703/Inst/MH/2015/RR-20	Dr Saibannavar Anita Ajit
